Integrated Advisors Network LLC Purchases 225 Shares of Hologic, Inc. (NASDAQ:HOLX)

Integrated Advisors Network LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 5.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 4,044 shares of the medical equipment provider’s stock after buying an additional 225 shares during the period. Integrated Advisors Network LLC’s holdings in Hologic were worth $289,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. bought a new position in shares of Hologic in the 4th quarter worth $27,000. Massmutual Trust Co. FSB ADV raised its stake in shares of Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares during the period. Allworth Financial LP raised its stake in shares of Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 179 shares during the period. Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 468 shares during the period. Finally, BKM Wealth Management LLC acquired a new stake in shares of Hologic in the 4th quarter valued at about $86,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on HOLX shares. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Friday, May 3rd. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. JPMorgan Chase & Co. lifted their target price on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their target price for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $85.60.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $71.47 on Wednesday. The business’s 50 day moving average price is $75.05 and its two-hundred day moving average price is $74.14. The company has a market cap of $16.68 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 2.39 and a beta of 1.00. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.06 earnings per share. On average, analysts predict that Hologic, Inc. will post 4.08 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.